{"id":"W2905371854","doi":"10.1002/hep.30417","title":"Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection","year":2018,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto Liver Centre; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; Genentech; Georgia Clinical and Translational Science Alliance; National Institute of Diabetes and Digestive and Kidney Diseases; Gilead Sciences; National Institutes of Health; American Association for the Study of Liver Diseases; Bristol-Myers Squibb","keywords":"Entecavir; Medicine; HBeAg; Hepatitis B virus; Internal medicine; Gastroenterology; Nucleoside analogue; Hepatocellular carcinoma; Clinical endpoint; Hepatitis B; Immunology; Virology; Nucleoside; Virus; HBsAg; Lamivudine; Clinical trial; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008449245,0.0003140407,0.0006956244,0.0001760033,0.0002493759,0.0002453503,0.0001419415,0.000478425,0.0009585205],"category_scores_gemma":[0.0009455596,0.0001738081,0.0004534664,0.000204246,0.0001588943,0.0003807319,0.0002246649,0.0005160659,0.0001640198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001921458,"about_ca_system_score_gemma":0.0004204469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004670875,"about_ca_topic_score_gemma":0.001394301,"domain_scores_codex":[0.9996146,0.0002080185,0.00005913365,0.00003519782,0.00005047156,0.00003256787],"domain_scores_gemma":[0.9996842,0.00008035498,0.00008563563,0.000009863807,0.00002664849,0.0001132151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1819805,0.006280723,0.4005896,0.001856787,0.001463837,0.00257144,0.0008257469,0.0007099739,0.01535463,0.0002677675,0.003241847,0.3848571],"study_design_scores_gemma":[0.04486614,0.2107219,0.7106097,0.0006311712,0.001712055,0.006715224,0.0007463936,0.002046975,0.004104466,0.0002738014,0.01752652,0.00004565658],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880393,0.009987963,0.0001341306,0.0003095708,0.00004693295,0.0001561454,0.00009762041,0.00000983211,0.001218418],"genre_scores_gemma":[0.9950618,0.003264068,0.0004386402,0.0004035445,0.00009785253,0.0001630444,0.0001302566,0.000002058615,0.0004386988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009585205,"threshold_uncertainty_score":0.004468441,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008483123138900803,"score_gpt":0.2540030218659991,"score_spread":0.2455198987270983,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}